Pharmaceutical

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Arena Pharmaceuticals, Inc. breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition Pfizer Inc. . Click here to learn more and participate in the action. On December 13, 2021, Arena announced that it ...

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) breached their fiduciary duties or violated the federal securities laws in connection with the company's acquisition Pfizer Inc. (NYSE: PFE).

Click here to learn more and participate in the action.

On December 13, 2021, Arena announced that it had entered into an agreement to be acquired by Pfizer in a deal valued at approximately $6.7 billion. Pursuant to the merger agreement, Arena shareholders will receive $100 in cash for each share of Arena common stock owned.

Bragar Eagel & Squire is concerned that Arena's board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Arena's stockholders.

If you own shares of Arena and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at mergers@bespc.com or telephone at (646) 860-9157, or by filling out this contact form . There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com . Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:
Bragar Eagel & Squire, P.C.
Melissa Fortunato, Esq.
Alexandra Raymond, Esq.
investigations@bespc.com
www.bespc.com


News Provided by GlobeNewswire via QuoteMedia

SHAREHOLDER ALERT: Weiss Law Investigates Biohaven Pharmaceutical Holding Company Ltd.

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") (NYSE: BHVN) in connection with the proposed acquisition of the Company by Pfizer Inc. ("Pfizer") (NYSE: PFE). Under the terms of the merger agreement, Pfizer will acquire all outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash. Biohaven common shareholders, including Pfizer, will also receive 0.5 of a share of New Biohaven per Biohaven common share, a new publicly traded company that will retain Biohaven's non-calcitonin gene-related peptide development stage pipeline compounds.

(PRNewsfoto/WeissLaw LLP)

If you own Biohaven shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
https://www.weisslaw.co/news-and-cases/bhvn
Or please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7 th Floor
New York , NY  10007
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Weiss Law is investigating whether (i) Biohaven's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Biohaven's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-alert-weiss-law-investigates-biohaven-pharmaceutical-holding-company-ltd-301544263.html

SOURCE Weiss Law

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

BIOHAVEN ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of BHVN and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) breached their fiduciary duties or violated the federal securities laws in connection with the company's acquisition by Pfizer, Inc. (NYSE: PFE).

Click here to learn more and participate in the action.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Pfizer to Acquire Biohaven Pharmaceuticals

Pfizer to commercialize NURTEC ® ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need

Expands Pfizer's innovative Internal Medicine pipeline to drive enhanced growth through 2030 and beyond

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA®

Data from studies of six medicines and pipeline candidates in more than 25 cancers to be presented

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that data for six approved medicines and pipeline candidates in more than 25 types of cancer will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 3-7. Presentations will feature new or updated findings from Merck's broad portfolio of cancer medicines: KEYTRUDA; WELIREG™ (belzutifan); LYNPARZA ® (olaparib, in collaboration with AstraZeneca); and LENVIMA ® (lenvatinib, in collaboration with Eisai). Additionally, Merck will present data from its diverse pipeline of immuno-therapeutic candidates, including the investigational anti-LAG-3 therapy favezelimab and the investigational anti-ILT3 therapy MK-0482.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Love Pharma Inc. Announces Closing of Financing

Love Pharma Inc. Announces Closing of Financing

Love Pharma Inc. ("LOVE" and or "the Company") (CSE:LUV)(FSE:G1Q0), announces it has completed the second tranche of a non-brokered private placement. The Company accepted subscriptions for 2,375,000 units at a price of $0.02 per unit, for gross proceeds of $47,500. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at $0.05 for a period of two years from the date of closing, subject to the option of the Company to accelerate the expiry date in the event that its shares trade at $0.15 or more for 10 consecutive days

The Company paid $3,800 in cash and issued 190,000 broker warrants on the same terms as noted above, to qualified finders. Securities issued pursuant to this tranche are subject to trading restrictions until September 7, 2022.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis

Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for MYFEMBREE ® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis. The FDA requires extended time to review additional information the Agency requested from the companies regarding bone mineral density. The extended Prescription Drug User Fee Act (PDUFA) goal date is August 6, 2022.

"We remain confident in the clinical profile of MYFEMBREE and its potential to become a therapeutic option for the management of endometriosis-associated pain," said Juan Camilo Arjona Ferreira, Chief Medical Officer of Myovant Sciences, Inc. "We will continue to work closely with the FDA to support the ongoing review of the sNDA."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×